

## ACRUX NOT REQUIRED TO FILE QUARTERLY CASH FLOW REPORTS

Acrux (ASX: ACR) has been advised by ASX that with immediate effect it is no longer required to file Appendix 4C quarterly cash flow reports under Listing Rule 4.7B.

### Contact

Jon Pilcher, Company Secretary – 0438 422 271

### About Acrux

[www.acrux.com.au](http://www.acrux.com.au)

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products marketed by licensees in the USA, one product approved in Europe, one product in registration in the USA and Europe and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.

